Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer
NCT ID: NCT03150056
Last Updated: 2022-08-10
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
TERMINATED
Clinical Phase
PHASE1
Total Enrollment
73 participants
Study Classification
INTERVENTIONAL
Study Start Date
2017-07-18
Study Completion Date
2021-06-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study aims to evaluate the combination of GSK525762 with other agents that have been shown to be effective in the treatment of CRPC or metastatic (m)CRPC. This study is designed to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) based on safety, tolerability, pharmacokinetic, and efficacy profiles of GSK525762 in combination with either abiraterone (Arm A) or enzalutamide (Arm B).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer
NCT02215096
Neoplasms
COMPLETED
PHASE1
CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate Cancer
NCT00075192
Prostatic Neoplasms
COMPLETED
PHASE1/PHASE2
Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer
NCT02566772
Metastatic Castration Resistant Prostate Cancer
COMPLETED
PHASE1
RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)
NCT02090114
Prostate Cancer
COMPLETED
PHASE2
A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT01283373
Prostate Cancer
COMPLETED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Solid Tumours
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
This will be a two-arm, open-label dose escalation and dose expansion cohort study.
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GSK525762 + Abiraterone (+ Prednisone) (Arm A)
Group Type
EXPERIMENTAL
GSK525762
Intervention Type
DRUG
GSK525762 will be administered.
Abiraterone
Intervention Type
DRUG
Abiraterone will be administered.
Prednisone
Intervention Type
DRUG
Prednisone will be administered as a concomitant medication in combination with abiraterone
GSK525762 + Enzalutamide (Arm B)
Group Type
EXPERIMENTAL
GSK525762
Intervention Type
DRUG
GSK525762 will be administered.
Enzalutamide
Intervention Type
DRUG
Enzalutamide will be administered.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GSK525762
GSK525762 will be administered.
Intervention Type
DRUG
Abiraterone
Abiraterone will be administered.
Intervention Type
DRUG
Enzalutamide
Enzalutamide will be administered.
Intervention Type
DRUG
Prednisone
Prednisone will be administered as a concomitant medication in combination with abiraterone
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Written informed consent provided.
* Males \>=18 years of age (at the time written consent is obtained for screening).
* Histologically confirmed adenocarcinoma of the prostate: screening and on-treatment biopsy is mandatory. If adequate number of paired biopsy samples are collected (\>=20 paired samples for each dose level in each Arm, unless an Arm is closed early), then further biopsy sampling will be considered based on available data; screening biopsy can be waived if participant had a recent biopsy after failure of the most recent therapy (within 30 days) and the biopsy sample is secured to be sent as screening biopsy for this study.
* Surgically or medically castrated, with testosterone levels of less than or equal to (\<=)50 nanograms per deciliter (ng/dL) (\<2.0 nanometer \[nM\]). If the participant is being treated with luteinizing hormone-releasing hormone (LHRH) agonists/antagonists (participant who have not undergone orchiectomy) this therapy must have been initiated at least 4 weeks prior to Week 1 Day 1 and must be continued throughout the study.
* Participants must have failed prior therapy with abiraterone, enzalutamide, or both:
1. Has completed at least 12 weeks of prior continuous therapy with abiraterone or enzalutamide in any prior line.
2. Lead-in dosing period for enzalutamide only will be required under the following circumstance:
(i) If the participant has enzalutamide discontinuation for \>7 days prior to dosing start with GSK525762 plus enzalutamide on trial, then a enzalutamide only lead-in dosing of 28 days is required.
(ii) If the participant has enzalutamide discontinuation for \<=7 days prior to dosing start with GSK525762 plus enzalutamide on trial, then an enzalutamide only lead-in dosing of 14 days is required.
(iii) If the participant is on continuous dosing with enzalutamide prior to dosing start with GSK525762 plus enzalutamide on trial, then participant can start on combined dosing at end of screening period.
(c) Lead-in dosing period for abiraterone only will be required: if the participant has abiraterone discontinuation for more than 3 days prior to dosing start with GSK525762 plus abiraterone on trial, then abiraterone only lead-in dosing of 7 days is required.
* One to two line(s) of prior taxane-based chemotherapy allowed. If docetaxel chemotherapy is used more than once, this will be considered as one regimen. Participants who have not received prior chemotherapy in any setting will qualify for study if they are ineligible for or refuse chemotherapy.
* Documented prostate cancer progression as assessed by the investigator with one of the following:
1. PSA progression defined by a minimum of 3 rising PSA levels with an interval of \>=1 week between each determination. The PSA value at screening must be \>=5 microgram (µg)/Liter (L) (5 ng/mL) if PSA is the only indication of progression; participants on systemic glucocorticoids for control of symptoms must have documented PSA progression by PCWG3 while on systemic glucocorticoids prior to commencing Week 1 Day 1 treatment.
2. Radiographic progression of soft tissue disease by PCWG3-modified RECIST 1.1 criteria or bone metastasis with 2 or more documented new bone lesions on a bone scan with or without PSA progression.
* ECOG performance status of 0 or 1.
* Life expectancy \>12 weeks.
* Able to swallow and retain orally administered medication.
* Must have adequate organ function.
* Male participants are eligible to participate if they agree to use contraceptive methods.
* Males \>=18 years of age (at the time written consent is obtained for screening).
* Histologically confirmed adenocarcinoma of the prostate: screening and on-treatment biopsy is mandatory. If adequate number of paired biopsy samples are collected (\>=20 paired samples for each dose level in each Arm, unless an Arm is closed early), then further biopsy sampling will be considered based on available data; screening biopsy can be waived if participant had a recent biopsy after failure of the most recent therapy (within 30 days) and the biopsy sample is secured to be sent as screening biopsy for this study.
* Surgically or medically castrated, with testosterone levels of less than or equal to (\<=)50 nanograms per deciliter (ng/dL) (\<2.0 nanometer \[nM\]). If the participant is being treated with luteinizing hormone-releasing hormone (LHRH) agonists/antagonists (participant who have not undergone orchiectomy) this therapy must have been initiated at least 4 weeks prior to Week 1 Day 1 and must be continued throughout the study.
* Participants must have failed prior therapy with abiraterone, enzalutamide, or both:
1. Has completed at least 12 weeks of prior continuous therapy with abiraterone or enzalutamide in any prior line.
2. Lead-in dosing period for enzalutamide only will be required under the following circumstance:
(i) If the participant has enzalutamide discontinuation for \>7 days prior to dosing start with GSK525762 plus enzalutamide on trial, then a enzalutamide only lead-in dosing of 28 days is required.
(ii) If the participant has enzalutamide discontinuation for \<=7 days prior to dosing start with GSK525762 plus enzalutamide on trial, then an enzalutamide only lead-in dosing of 14 days is required.
(iii) If the participant is on continuous dosing with enzalutamide prior to dosing start with GSK525762 plus enzalutamide on trial, then participant can start on combined dosing at end of screening period.
(c) Lead-in dosing period for abiraterone only will be required: if the participant has abiraterone discontinuation for more than 3 days prior to dosing start with GSK525762 plus abiraterone on trial, then abiraterone only lead-in dosing of 7 days is required.
* One to two line(s) of prior taxane-based chemotherapy allowed. If docetaxel chemotherapy is used more than once, this will be considered as one regimen. Participants who have not received prior chemotherapy in any setting will qualify for study if they are ineligible for or refuse chemotherapy.
* Documented prostate cancer progression as assessed by the investigator with one of the following:
1. PSA progression defined by a minimum of 3 rising PSA levels with an interval of \>=1 week between each determination. The PSA value at screening must be \>=5 microgram (µg)/Liter (L) (5 ng/mL) if PSA is the only indication of progression; participants on systemic glucocorticoids for control of symptoms must have documented PSA progression by PCWG3 while on systemic glucocorticoids prior to commencing Week 1 Day 1 treatment.
2. Radiographic progression of soft tissue disease by PCWG3-modified RECIST 1.1 criteria or bone metastasis with 2 or more documented new bone lesions on a bone scan with or without PSA progression.
* ECOG performance status of 0 or 1.
* Life expectancy \>12 weeks.
* Able to swallow and retain orally administered medication.
* Must have adequate organ function.
* Male participants are eligible to participate if they agree to use contraceptive methods.
Exclusion Criteria
* Surgery or local prostatic intervention (excluding a prostatic biopsy) less than 28 days of Week 1 Day 1.
* Participants with neuroendocrine and/or small cell CRPC.
* Recent prior therapy, defined as:
1. Any investigational or approved non-biologic anti-cancer drug within 14 days prior to the first dose of GSK525762 and abiraterone/enzalutamide.
2. Any nitrosoureas or mitomycin C within 42 days prior to the first dose of GSK525762 and abiraterone/enzalutamide.
3. Any anti-cancer biologic agents within five half-lives prior to the first dose of GSK525762 and abiraterone/enzalutamide.
4. If the participant received radiotherapy \<90 days prior to study treatment, the irradiated lesion cannot be the only lesion used for evaluating response.
5. Any major surgery within 28 days prior to the first dose of GSK525762 and abiraterone/enzalutamide.
* Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated respiratory, hepatic, renal, cardiac disease, or clinically significant bleeding episodes). Any serious and/or unstable pre-existing medical (aside from malignancy), psychiatric disorder, or other conditions that could interfere with participant's safety, obtaining informed consent or compliance to the study procedures, in the opinion of the Investigator; systolic blood pressure higher than 150 millimeter of mercury (mmHg) or diastolic blood pressure higher than 90 mmHg found on 2 separate occasions separated by 1 week, despite adequate therapy, will be defined as uncontrolled hypertension; uncontrolled diabetes mellitus (despite therapeutic, compliance intervention) as defined by a hemoglobin A1c (HbA1c) level more than 8% and/or occurrence of more than 2 episodes of ketoacidosis in the 12 months prior to the first dose of study drug.
* Cardiac abnormalities as evidenced by any of the following:
1. Baseline QT interval corrected for heart rate by Fridericia's formula (QTcF) interval \>=480 milliseconds (msec).
2. Clinically significant conduction abnormalities or arrhythmias, such as participants with second degree (Type II) or third degree atrio-ventricular block.
3. History or evidence of current \>=Class II congestive heart failure as defined by New York Heart Association (NYHA).
4. History of acute coronary syndromes (including unstable angina and myocardial infarction), coronary angioplasty, or stenting within the past 3 months. Participants with a history of stent placement requiring ongoing anti-coagulant therapy (e.g., clopidogrel, prasugrel) will not be permitted to enroll.
5. Known cardiac metastasis.
* Participants with history of known bleeding disorder(s) or history of clinically significant hemorrhage (e.g., gastrointestinal, neurologic), within the past 6 months.
* Therapeutic-dose anticoagulation (e.g., warfarin, low-molecular weight heparin \[LMWH\], or novel oral anticoagulants) must be discontinued and coagulation parameters must be normalized prior to the first dose of GSK525762 and abiraterone/enzalutimide. Prophylactic anticoagulation, with low doses (per standard practice) of agents such as LMWH, direct thrombin inhibitors, or factor Xa inhibitors is permitted.
* Concurrent use of high dose aspirin (doses up to 81 milligrams (mg) oral dose daily allowed, or 100 mg, as per country standards) and non-steroidal anti-inflammatory drugs (NSAIDS), except for where NSAIDs provide documented benefit over other analgesics, and then to be used with caution including concomitant use of proton pump inhibitors).
* Any acute toxicities due to prior chemotherapy and / or radiotherapy that have not resolved to a National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0 grade \<=1 with the exception of chemotherapy induced alopecia and grade 2 peripheral neuropathy.
* The participant has an active second malignancy other than curatively resected basal cell or squamous cell carcinoma of the skin, in situ carcinoma of the bladder, or other cancers for which they are treated with curative intent with no active disease in the 3 years prior to enrollment.
* Participants with known symptomatic brain metastasis are not suitable for enrolment. Participants with asymptomatic, stable, treated brain metastases are eligible for study entry.
* History of seizure within 6 months of study treatment initiation or any condition that may predispose participant to seizure (e.g., prior cortical stroke or significant brain trauma) or who are currently being treated with cytochrome P450 enzyme inducing anti-epileptic drugs for seizures (use of anti-epileptic drugs to control pain is allowed in participants not suffering from seizures unless drug is excluded due to Cytochrome (CY)P3A4 induction - phenytoin, carbamazepine, phenobarbital).
* History of loss of consciousness or transient ischemic attack within 12 months prior to enrollment.
* Participants with symptomatic or impending cord compression unless appropriately treated beforehand and clinically stable and asymptomatic.
* Current use of a prohibited medication or planned use of any forbidden medications during treatment with GSK525762 and abiraterone/enzalutamide. This includes medications that are potent inducers or inhibitors of CYP3A4 enzymes or strong inhibitors of CYP2C8.
* Participants with gastrointestinal disorders likely to interfere with absorption of the study medication.
* Participants with known bleeding diathesis.
* Current active liver or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones, liver metastases or otherwise stable chronic liver disease per investigator assessment).
* Initiating bisphosphonate or denosumab therapy or adjusting dose/regimen within 3 months prior to Week 1 Day 1. Participants on a stable bisphosphonate or denosumab therapy are eligible and may continue.
* Any serious known immediate or delayed hypersensitivity reaction to GSK525762 or idiosyncrasy to drugs chemically related to the investigational drugs. Additionally, any known hypersensitivity to either enzalutamide, abiraterone or any excipients would be excluded.
* Known history of human immunodeficiency virus (HIV).
* Presence of hepatitis B surface antigen (HBsAg) or positive hepatitis C antibody test result at screening.
* Participants with neuroendocrine and/or small cell CRPC.
* Recent prior therapy, defined as:
1. Any investigational or approved non-biologic anti-cancer drug within 14 days prior to the first dose of GSK525762 and abiraterone/enzalutamide.
2. Any nitrosoureas or mitomycin C within 42 days prior to the first dose of GSK525762 and abiraterone/enzalutamide.
3. Any anti-cancer biologic agents within five half-lives prior to the first dose of GSK525762 and abiraterone/enzalutamide.
4. If the participant received radiotherapy \<90 days prior to study treatment, the irradiated lesion cannot be the only lesion used for evaluating response.
5. Any major surgery within 28 days prior to the first dose of GSK525762 and abiraterone/enzalutamide.
* Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated respiratory, hepatic, renal, cardiac disease, or clinically significant bleeding episodes). Any serious and/or unstable pre-existing medical (aside from malignancy), psychiatric disorder, or other conditions that could interfere with participant's safety, obtaining informed consent or compliance to the study procedures, in the opinion of the Investigator; systolic blood pressure higher than 150 millimeter of mercury (mmHg) or diastolic blood pressure higher than 90 mmHg found on 2 separate occasions separated by 1 week, despite adequate therapy, will be defined as uncontrolled hypertension; uncontrolled diabetes mellitus (despite therapeutic, compliance intervention) as defined by a hemoglobin A1c (HbA1c) level more than 8% and/or occurrence of more than 2 episodes of ketoacidosis in the 12 months prior to the first dose of study drug.
* Cardiac abnormalities as evidenced by any of the following:
1. Baseline QT interval corrected for heart rate by Fridericia's formula (QTcF) interval \>=480 milliseconds (msec).
2. Clinically significant conduction abnormalities or arrhythmias, such as participants with second degree (Type II) or third degree atrio-ventricular block.
3. History or evidence of current \>=Class II congestive heart failure as defined by New York Heart Association (NYHA).
4. History of acute coronary syndromes (including unstable angina and myocardial infarction), coronary angioplasty, or stenting within the past 3 months. Participants with a history of stent placement requiring ongoing anti-coagulant therapy (e.g., clopidogrel, prasugrel) will not be permitted to enroll.
5. Known cardiac metastasis.
* Participants with history of known bleeding disorder(s) or history of clinically significant hemorrhage (e.g., gastrointestinal, neurologic), within the past 6 months.
* Therapeutic-dose anticoagulation (e.g., warfarin, low-molecular weight heparin \[LMWH\], or novel oral anticoagulants) must be discontinued and coagulation parameters must be normalized prior to the first dose of GSK525762 and abiraterone/enzalutimide. Prophylactic anticoagulation, with low doses (per standard practice) of agents such as LMWH, direct thrombin inhibitors, or factor Xa inhibitors is permitted.
* Concurrent use of high dose aspirin (doses up to 81 milligrams (mg) oral dose daily allowed, or 100 mg, as per country standards) and non-steroidal anti-inflammatory drugs (NSAIDS), except for where NSAIDs provide documented benefit over other analgesics, and then to be used with caution including concomitant use of proton pump inhibitors).
* Any acute toxicities due to prior chemotherapy and / or radiotherapy that have not resolved to a National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0 grade \<=1 with the exception of chemotherapy induced alopecia and grade 2 peripheral neuropathy.
* The participant has an active second malignancy other than curatively resected basal cell or squamous cell carcinoma of the skin, in situ carcinoma of the bladder, or other cancers for which they are treated with curative intent with no active disease in the 3 years prior to enrollment.
* Participants with known symptomatic brain metastasis are not suitable for enrolment. Participants with asymptomatic, stable, treated brain metastases are eligible for study entry.
* History of seizure within 6 months of study treatment initiation or any condition that may predispose participant to seizure (e.g., prior cortical stroke or significant brain trauma) or who are currently being treated with cytochrome P450 enzyme inducing anti-epileptic drugs for seizures (use of anti-epileptic drugs to control pain is allowed in participants not suffering from seizures unless drug is excluded due to Cytochrome (CY)P3A4 induction - phenytoin, carbamazepine, phenobarbital).
* History of loss of consciousness or transient ischemic attack within 12 months prior to enrollment.
* Participants with symptomatic or impending cord compression unless appropriately treated beforehand and clinically stable and asymptomatic.
* Current use of a prohibited medication or planned use of any forbidden medications during treatment with GSK525762 and abiraterone/enzalutamide. This includes medications that are potent inducers or inhibitors of CYP3A4 enzymes or strong inhibitors of CYP2C8.
* Participants with gastrointestinal disorders likely to interfere with absorption of the study medication.
* Participants with known bleeding diathesis.
* Current active liver or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones, liver metastases or otherwise stable chronic liver disease per investigator assessment).
* Initiating bisphosphonate or denosumab therapy or adjusting dose/regimen within 3 months prior to Week 1 Day 1. Participants on a stable bisphosphonate or denosumab therapy are eligible and may continue.
* Any serious known immediate or delayed hypersensitivity reaction to GSK525762 or idiosyncrasy to drugs chemically related to the investigational drugs. Additionally, any known hypersensitivity to either enzalutamide, abiraterone or any excipients would be excluded.
* Known history of human immunodeficiency virus (HIV).
* Presence of hepatitis B surface antigen (HBsAg) or positive hepatitis C antibody test result at screening.
Minimum Eligible Age
18 Years
Eligible Sex
MALE
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Los Angeles, California, United States
Site Status
GSK Investigational Site
Baltimore, Maryland, United States
Site Status
GSK Investigational Site
Towson, Maryland, United States
Site Status
GSK Investigational Site
Boston, Massachusetts, United States
Site Status
GSK Investigational Site
Detroit, Michigan, United States
Site Status
GSK Investigational Site
St Louis, Missouri, United States
Site Status
GSK Investigational Site
New York, New York, United States
Site Status
GSK Investigational Site
Philadelphia, Pennsylvania, United States
Site Status
GSK Investigational Site
Madison, Wisconsin, United States
Site Status
GSK Investigational Site
Sydney, New South Wales, Australia
Site Status
GSK Investigational Site
Clayton, Victoria, Australia
Site Status
GSK Investigational Site
Melbourne, Victoria, Australia
Site Status
GSK Investigational Site
Barcelona, , Spain
Site Status
GSK Investigational Site
Barcelona, , Spain
Site Status
GSK Investigational Site
Madrid, , Spain
Site Status
GSK Investigational Site
Málaga, , Spain
Site Status
GSK Investigational Site
Sabadell (Barcelona), , Spain
Site Status
GSK Investigational Site
Santander, , Spain
Site Status
GSK Investigational Site
Sutton, London, United Kingdom
Site Status
GSK Investigational Site
Glasgow, , United Kingdom
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Australia
Spain
United Kingdom
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-003416-13
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
204697
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Study of Dose Escalation of Abiraterone Actetate in Prostate Cancer
NCT03458247
COMPLETED
PHASE2
A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer
NCT01228760
COMPLETED
PHASE1
Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer
NCT00473746
COMPLETED
PHASE1/PHASE2
A Phase I Dose-Escalation Study of BMS-641988 in Patients With Castration-Resistant Prostate Cancer
NCT00326586
COMPLETED
PHASE1
Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
NCT00887198
COMPLETED
PHASE3
Study of Abiraterone Acetate in Subjects With Metastatic Castration Resistant Prostate Cancer
NCT04056754
COMPLETED
PHASE3
Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy
NCT02217566
COMPLETED
PHASE2
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer
NCT02607228
TERMINATED
PHASE1/PHASE2
A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer
NCT01084759
COMPLETED
NA
An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma
NCT00544440
COMPLETED
PHASE2
ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer
NCT03456804
COMPLETED
PHASE2
Androgen Blockade Therapy With or Without Zoledronic Acid in Treating Patients With Prostate Cancer and Bone Metastases
NCT00685646
COMPLETED
PHASE3
Darolutamide + Androgen Deprivation Therapy (ADT) in Chinese Men With High Risk, Nonmetastatic Prostate Cancer
NCT05171387
COMPLETED
PHASE2
First-Time-in-Human Study of GSK5471713 in Adults With mCRPC
NCT07332455
NOT_YET_RECRUITING
PHASE1/PHASE2
Phase I/II Study of ASP9521 in Castrate-Resistant Prostate Cancer (CRPC) Patients
NCT01352208
TERMINATED
PHASE1/PHASE2
S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy
NCT01309672
COMPLETED
PHASE2
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
NCT05800665
RECRUITING
PHASE1
EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer
NCT01360840
COMPLETED
PHASE2
A Study to Determine Enzalutamide Long-term Safety and Efficacy After Anti-androgen Therapy for CRPC
NCT02669147
COMPLETED
Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer
NCT01217697
APPROVED_FOR_MARKETING
A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer
NCT01337518
SUSPENDED
PHASE1
A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
NCT03137758
TERMINATED
PHASE1
A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT02162836
COMPLETED
PHASE1
Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors
NCT05974774
RECRUITING
PHASE3
HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT05553639
TERMINATED
PHASE1/PHASE2